Ad
related to: pca3 test results interpretation and cancer definition quizlet
Search results
Results From The WOW.Com Content Network
n/a Ensembl ENSG00000225937 n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) Chr 9: 76.69 – 76.86 Mb n/a PubMed search n/a Wikidata View/Edit Human Prostate cancer antigen 3 (PCA3, also referred to as DD3) is a gene that expresses a non-coding RNA. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in prostate cancer ...
Prostate cancer antigen 3 is a urine test that detects the overexpression of the PCA3 gene, an indicator of prostate cancer. [32] [46] [47] [44] ConfirmMDx is performed on tissue taken during a prostate biopsy. The test identifies men with clinically significant prostate cancer who would benefit from further testing and treatment.
The screening can present abnormal results even when a man does not have cancer (known as a false-positive result), or normal results even when a man does have cancer (known as a false-negative result). [13] False-positive test results can cause confusion and anxiety in men, and can lead to unnecessary prostate biopsies, a procedure which ...
Tumor markers can be molecules that are produced in higher amounts by cancer cells than normal cells, but can also be produced by other cells from a reaction with the cancer. [2] The markers can't be used to give patients a diagnosis but can be compared with the result of other tests like biopsy or imaging. [2]
Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder.Abnormal growth of the prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels.
The false positive rate (FPR) is the proportion of all negatives that still yield positive test outcomes, i.e., the conditional probability of a positive test result given an event that was not present. The false positive rate is equal to the significance level. The specificity of the test is equal to 1 minus the false positive rate.
In clinical practice, post-test probabilities are often just estimated or even guessed. This is usually acceptable in the finding of a pathognomonic sign or symptom, in which case it is almost certain that the target condition is present; or in the absence of finding a sine qua non sign or symptom, in which case it is almost certain that the target condition is absent.
Pan-cancer studies aim to detect the genes whose mutation is conducive to oncogenesis, as well as recurrent genomic events or aberrations between different tumors.For these studies, it is necessary to standardize the data between multiple platforms, establishing criteria between different researchers to work on the data and present the results.